Skip to main content

Intellia Therapeutics, Inc.

corporate_fare Company Profile

Intellia Therapeutics, Inc.

NTLA·NASDAQ·Life Sciences·CIK 0001652130

Intellia Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments using CRISPR gene editing and other core technologies. The company aims to develop and commercialize potentially curative treatments for people with severe diseases. Intellia applies its proprietary technologies, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (LNPs), to develop product candidates. Its lead product candidates are lonvoguran ziclumeran (lonvo-z or NTLA-2002) for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z or NTLA-2001) for transthyretin (ATTR) amyloidosis. These are the first in vivo genome editing product candidates to enter Phase 3 development. These candidates are designed to treat diseases with a single intravenous (IV) infusion administered in an outpatient setting. Lonvo-z and nex-z are currently in Phase 3 clinical development. The company is preparing for the planned commercial launch of lonvo-z in the first half of 2027. Intellia and its collaboration partners are also advancing additional clinical and preclinical product candidates. The company leverages collaborations, including one with Regeneron Pharmaceuticals, Inc. (Regeneron), to expand and accelerate product candidate development.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for NTLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NTLA spans 8-K, 10-Q, 424B5.

Recent high-impact activity:

  • Intellia Outlines Lonvo-z Launch Strategy Ahead of March 10, 2027 PDUFA
  • Intellia's One-Time CRISPR HAE Therapy Shows Four-Year Durability Ahead of March PDUFA
  • Intellia Posts $127.5M Q3 Loss as Cash Burn Accelerates
  • FDA Accepts Intellia's BLA for Lonvo-z with Priority Review; PDUFA Date Set for March 10, 2027
  • FDA Accepts Intellia's BLA for Lonvo-z with Priority Review, PDUFA Date March 10, 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$67.67M
Net Income
-$412.69M
Diluted EPS
-$3.81
Op. Cash Flow
-$394.74M
Free Cash Flow
-$395.87M
Operating Income
-$440.99M
Cash & Equivalents
$155.46M
Debt / Equity
0.00×
Net Margin
-6.10×
Shares Outstanding
116.32M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076550

Short Interest & Short Volume

11.05 days to cover

FINRA reported short interest of 44,361,762 shares in NTLA as of the October 30, 2026 settlement, a 0.2% decrease from the prior period — about 11.1 days to cover at its recent average daily volume. On November 20, 2026, 52.5% of NTLA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)44,361,762 shares as of October 30, 2026
Change vs prior period▼ 0.2%
Days to cover11.05 at avg daily volume of 4,013,427
Daily short volume (FINRA facilities)52.5% of 4,204,989 shares on November 20, 2026
5-day average short volume53.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for NTLA, detected from its recent SEC filings.

1 shelf registration

Shelf Renewal Replaces Expiring Registration · Existing ATM Capacity Re-Registered

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$10 +0.01% today
52-week range · as of 2026-11-12 $7.95 – $18.48
Market cap
$1.4B
Volume
15.2M (2.8× avg)
3-mo avg 5.4M
Live data · 2026-11-22 09:57 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NTLA - Latest Insights

NTLA
Nov 12, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.60
Real-time Price: $10.00 info
Change: -$0.5994 (-6%) info
Market Cap: $1.404B info
NTLA
Nov 12, 2026, 10:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.72
Real-time Price: $10.00 info
Change: -$0.7194 (-7%) info
Market Cap: $1.404B info
NTLA
Nov 05, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $12.30
Real-time Price: $10.00 info
Change: -$2.30 (-19%) info
Market Cap: $1.404B info
NTLA
Sep 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.74
Real-time Price: $10.00 info
Change: -$2.74 (-22%) info
Market Cap: $1.404B info
NTLA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.69
Real-time Price: $10.00 info
Change: -$3.69 (-27%) info
Market Cap: $1.404B info
NTLA
Sep 04, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.75
Real-time Price: $10.00 info
Change: -$2.75 (-22%) info
Market Cap: $1.404B info
NTLA
Sep 04, 2026, 8:50 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.80
Real-time Price: $10.00 info
Change: -$2.80 (-22%) info
Market Cap: $1.404B info
NTLA
Aug 06, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.54
Real-time Price: $10.00 info
Change: -$1.54 (-13%) info
Market Cap: $1.404B info
NTLA
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.76
Real-time Price: $10.00 info
Change: -$0.7594 (-7%) info
Market Cap: $1.404B info
NTLA
Jun 15, 2026, 3:47 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.43
Real-time Price: $10.00 info
Change: -$4.43 (-31%) info
Market Cap: $1.404B info
NTLA
Jun 15, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $12.75
Real-time Price: $10.00 info
Change: -$2.75 (-22%) info
Market Cap: $1.404B info
NTLA
Jun 15, 2026, 8:52 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.75
Real-time Price: $10.00 info
Change: -$2.75 (-22%) info
Market Cap: $1.404B info
NTLA
Jun 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $12.22
Real-time Price: $10.00 info
Change: -$2.22 (-18%) info
Market Cap: $1.404B info
NTLA
May 11, 2026, 7:51 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $10.00 info
Change: -$3.90 (-28%) info
Market Cap: $1.404B info
NTLA
May 11, 2026, 7:49 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.79
Real-time Price: $10.00 info
Change: -$3.79 (-28%) info
Market Cap: $1.404B info
NTLA
May 11, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.31
Real-time Price: $10.00 info
Change: -$4.31 (-30%) info
Market Cap: $1.404B info
NTLA
Apr 30, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.54
Real-time Price: $10.00 info
Change: -$3.54 (-26%) info
Market Cap: $1.404B info
NTLA
Apr 30, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.51
Real-time Price: $10.00 info
Change: -$3.51 (-26%) info
Market Cap: $1.404B info
NTLA
Apr 29, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $12.43
Real-time Price: $10.00 info
Change: -$2.43 (-20%) info
Market Cap: $1.404B info
NTLA
Apr 27, 2026, 9:13 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $14.17
Real-time Price: $10.00 info
Change: -$4.17 (-29%) info
Market Cap: $1.404B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets